In a lab in Regensburg, Germany, a tiny protein glitch is giving big hope. Dr. Ralph Witzgall and his team have cracked open the mystery of how a rare genetic disease damages the kidneys—and found that a drug already used to treat cancer might slow it down. The condition, called nail-patella syndrome, affects about 1 in 50,000 people. While it’s known for misshapen fingernails and kneecaps, its real danger lies in the kidneys. Over time, the disease can erode kidney function, sometimes leading to total kidney failure. For decades, doctors could do little to stop it.
Now, the Regensburg team has uncovered the root problem. People with nail-patella syndrome have mutations in a gene called LMX1B. This gene helps build a protein that’s vital for kidney filter cells called podocytes. These cells act like a sieve, keeping important proteins in the blood while flushing out waste. But when the LMX1B protein can’t bind to zinc—a trace element the body needs—the protein crumples like a bent wire. The body’s cleanup crew, called the proteasome, spots the broken protein and destroys it too soon. Without enough working LMX1B, the kidney’s filter breaks down, and protein leaks into the urine—a clear sign of damage.
The breakthrough came when the researchers tested bortezomib, a drug approved for multiple myeloma, a type of blood cancer. Bortezomib works by slowing down the proteasome. In mice engineered to mimic nail-patella syndrome, the drug helped the faulty LMX1B protein survive longer. Seven days after kidney damage was triggered, untreated mice showed severe loss of foot processes—tiny structures on podocytes that are essential for filtering. But in mice treated with bortezomib, those structures were largely preserved. Protein leakage dropped sharply, and kidney function stabilized.
This isn’t a cure—yet. The study was done in mice, and human trials are still ahead. But for a disease with no treatment options, even a starting point is powerful. The fact that bortezomib is already approved for other uses could speed up the path to testing it in patients. The team included scientists from the University of Regensburg and the Technical University of Munich, and their work was published in Nature Communications in 2026.
For families living with nail-patella syndrome, this discovery offers something rare: a glimpse of a future where kidney damage might be preventable. Science moves step by step, but sometimes, a single step reveals a whole new path forward.